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Objective: Surgical intervention is an option for treating the remodeled and dilated
left ventricles of patients with heart failure. Providing end-diastolic support with an
innovative mesh-like cardiac support device reduces mechanical stress, improves
function, and reverses cardiac remodeling in animal models without safety issues.
The objective of this study was to review the global clinical safety and feasibility
experience of this device.
Methods: The Acorn CorCap cardiac support device (Acorn Cardiovascular, Inc, St
Paul, Minn) has been implanted worldwide in more than 130 patients with dilated
cardiomyopathy with or without concomitant cardiac surgery. The device is posi-
tioned around the ventricles and given a custom fit. A series of 48 patients were
implanted with the device in initial safety and feasibility studies, of whom 33 also
received concomitant cardiac surgery.
Results: At implantation, 11 patients were in New York Heart Association class II,
33 were in class III, and 4 were in class IV. The average CorCap implantation time
was 27 minutes. The mean intraoperative reduction in left ventricular end-diastolic
dimension was 4.6%  1%. There were no device-related intraoperative compli-
cations. Eight early and 9 late deaths occurred during follow-up extending to 24
months. Actuarial survival was 73% at 12 months and 68% at 24 months. There
were no device-related adverse events or evidence of constrictive disease, and
coronary artery flow reserve was maintained. Ventricular chamber dimensions
decreased, whereas ejection fraction and New York Heart Association class were
improved in patients overall and in those patients implanted with the CorCap device
without concomitant operations.
Conclusions: The CorCap device appears safe for patients with dilated cardiomy-
opathy. Randomized clinical trials are underway in Europe, Australia, and North
America.
Heart failure is characterized by a number of important degenera-tive changes in cardiac structure and function. Alterations are seenat various levels, including gene expression, cell organelle integ-rity, and cell shape and size, as well as organization of musclefibers and extracellular matrix. Changes in structure might becompensatory in the early phases of heart failure1,2 but ultimately
become maladaptive, contributing to a progressive loss of cardiac function. After an
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initial insult, the heart compensates with a number of acute
adaptive mechanisms to maintain adequate cardiac output.
Cardiac dilation and activation of neurohormones serve to
maintain arterial pressure and perfusion of vital organs.
However, dilation increases biomechanical wall stress and
cardiac myocyte stretching, which contribute to the devel-
opment of heart failure. Remodeling of cardiac structure and
function in response to injury is a well-established hallmark
in the progression of heart failure and is predictive of
increased mortality risk.3-6
Medical therapy, such as that represented by angiotensin-
converting enzyme inhibitors and -blockers, is the stan-
dard of care for management of heart failure. However,
numerous signaling pathways implicated in the promotion
and progression of heart failure suggest that drugs might not
provide all-encompassing protection against deterioration in
cardiac structure and function. Even multidrug regimens
might not prevent disease progression, suggesting the need
for alternative approaches. Surgical therapies intended to
unload the heart have received considerable recent atten-
tion. One such means is represented by the Acorn CorCap
cardiac support device (CSD; Acorn Cardiovascular, Inc, St
Paul, Minn), a mesh-like implantable device that is surgi-
cally positioned around the heart and adjusted to provide
circumferential diastolic support. The CSD is intended to
reduce wall stress and myocyte overstretching during end
diastole and periodic hemodynamic overload conditions. By
reducing or limiting the stress and stretching on the myo-
cardium, a key component of the remodeling process might
be halted or reversed.
Methods
The CSD is made from a mesh-like polyester fabric (Figure 1). The
fabric is constructed from a multifilamentous yarn to provide
high-strength and fatigue-resistant characteristics while maintain-
ing flexibility. A knit construction was chosen for the fabric to
impart tear and ravel resistance. The device is designed with
bidirectional compliance, providing greater circumference support
compared with the base-to-apex direction. This has the effect of
reshaping the heart to a more ellipsoidal shape. The CSD is
available in 6 sizes, with the final fitting performed by the surgeon
for the specific heart.
Appropriate patients for CSD implantation are adults with
systolic heart failure of ischemic or idiopathic cause with left
ventricular dilation. Patients might also require reparative cardiac
surgery, such as mitral valve repair-replacement or coronary artery
bypass grafting. Their New York Heart Association (NYHA)
functional class should be III or early IV. Typically, these patients
have debilitating symptoms despite aggressive treatment with car-
diac medications or show evidence of deterioration despite their
medications.
The upper inclusion limit for ejection fraction in this study was
35%, except for patients receiving concomitant mitral valve sur-
gery, in whom a limit of 45% was applied. Patients with primary
diastolic dysfunction or restrictive disease were excluded. Previous
cardiac surgery was not a contraindication, unless patent coronary
artery grafts might be compromised by the presence of the CSD or
adhesions might prevent proper CSD placement. Patients in end-
stage NYHA class IV receiving continuous intravenous inotropic
agents or mechanical support were excluded.
If the device is used as sole therapy, the CSD can be implanted
off pump. The device can also be implanted in conjunction with
additional reparative operations on the heart that are done during
cardiopulmonary bypass. In these cases device implantation should
be started during pump support to facilitate placement of the
posterior atrioventricular groove sutures. The final fitting of the
device is accomplished with the patient off pump with a full and
beating heart to ensure appropriate fitting. Additional techniques
involving minimally invasive approaches are in development.
After sternotomy, the pericardium is opened, and the diameter
of the left ventricle at the midpapillary muscle level is measured by
Figure 1. CSD structure. The CSD is a polyester knit construction
with compliance characteristics designed to encourage benefi-
cial reverse remodeling in dilated cardiomyopathy: A, photograph
of an isolated area of open-weave construction (original magni-
fication approximately 2.5); B, scanning electron microscopy
photograph showing node (knot; original magnification approxi-
mately 70).
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using transesophageal echocardiography. The appropriate CSD
size is selected by measuring the heart’s circumference and base-
to-apex dimension. A measuring tape or cord is placed around the
heart at the base to approximate the circumference, and the length
of the heart is measured from the base to the apex anteriorly. These
2 measurements are then used to select the appropriate size device
according to a sizing chart provided on the device package.
Once chosen, the CSD is positioned around the ventricles, with
particular care to ensure that the hemline lies above or just below
the atrioventricular groove. A series of 4-0 polypropylene sutures
is used to secure the device in place around the base of the heart,
starting in the posterior region and working laterally. Excess fabric
is accumulated anteriorly by using a specially designed clamp. The
excess material is then removed, and a new anterior seam is
formed (Figure 2). We seek to obtain a snug fit, which might result
in a slight reduction in the diameter of the heart, as measured by
means of transesophageal echocardiography, but avoids any re-
duction greater than 10% to minimize the potential for any adverse
events related to device fit. This snug fit ensures that the CSD
relieves a portion of mechanical stress and stretching in the ven-
tricular wall.
As of April 1, 2002, a total of 130 patients have received the
CSD. Patients include various safety study participants and those
enrolled in global randomized clinical trials currently underway in
Europe and the United States. Results from the randomized trials
will not be available until study enrollment and follow-up are
complete. Thus this report will focus on patients receiving the CSD
who are not enrolled in these randomized trials. Ethics committee
approval was obtained at participating institutions before entry of
patients into this safety study.
Initial safety studies included a series of 29 patients enrolled at
Charite´ Universita¨tsklinikum, Humboldt-Universita¨t zu, Berlin,
Germany, between April 1999 and July 2000. Of the 29 patients,
12 required no additional cardiac surgery other than the CSD
implantation, and the remainder had some type of concomitant
cardiac surgery. The majority of these procedures were mitral
valve repairs or replacements. The initial safety studies also in-
cluded a group of 5 patients with ischemic heart disease who were
enrolled at the Austin and Repatriation Medical Centre, Mel-
bourne, Australia. Coronary artery bypass grafting was performed
on all of the patients concomitant with CSD implantation. None of
these patients required valve repair or replacement. Coronary
artery angiography was performed at 6 months’ follow-up to
evaluate graft patency.
A final group of 14 nonrandomized patients was also included.
Three patients required no concomitant surgery; 7 underwent valve
repair or replacement, 2 had coronary artery bypass operations,
and 2 had both bypass grafting and valve repair or replacement. All
of these groups combine for a total of 48 initial safety study
patients. Results are reported as means  SD (range) unless
otherwise stated.
Inclusion and exclusion criteria for patients in these safety
studies are summarized in Table 1. During the initial experience, it
became important to exclude patients with very advanced or late-
stage heart failure because of a very high operative risk. A series
Figure 2. Positioning and securing the CSD. The CSD hemline is
attached near the atrioventricular groove through a series of
interrupted sutures, starting with the posterior aspect. An anterior
seam is used to create the proper device fit.
TABLE 1. Major inclusion and exclusion criteria
Inclusion Exclusion
Dilated cardiomyopathy:
ischemic or nonischemic
Stable and optimal medical
management
Adult (18-80 y)
Indexed LVEDD 30 mm/mm2
LVEF 35% or LVEF 45% for
CSD valve surgery
History of NYHA III or early
stage IV
Acceptable renal function
(creatinine 3.5 ml/dL),
hepatic function (SGOT and
SGPT 2  normal),
pulmonary function (FEV1
1.5 L)
Current or anticipated need
for LVAD or total
artificial heart
Likelihood of existing
cardiothoracic adhesions
preventing proper device
placement
Patent CABG
NYHA IV dependent on
intravenous inotropes
NYHA IV dependent on
intravenous inotropes
Late-stage heart failure
with increased surgical
risk
Acute myocardial infarction
within 3 mo
Hemodynamically unstable
or uncontrolled
arrhythmias
Comorbid condition with
life expectancy 2 y
SGOT, Aspartate aminotransferase; SGPT, alanine aminotransferase; FEV1,
forced expiratory volume in 1 second; LVAD, left ventricular assist device;
CABG, coronary artery bypass grafting.
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of 10 criteria were determined, representing late-stage heart failure
(Table 2). Patients with 4 or more of these criteria were excluded
from the study.
Patient follow-up was scheduled for 3, 6, 12, and 18 to 24
months after CSD implantation. Evaluation and testing included
clinical assessment, echocardiography (left ventricular end-dia-
stolic dimension [LVEDD], left ventricular end-systolic dimen-
sion, and left ventricular ejection fraction [LVEF]), and recording
of any adverse events. Quality-of-life instruments included the
Minnesota Living with Heart Failure Questionnaire7,8 and the
Uniscale (visual analog scale).9 A group of 15 patients was also
entered into a substudy to investigate the effect of the CSD on
diastolic function. Baseline cardiac catheterization was performed
before device implantation and at 3, 6, and 12 months’ follow-up.
Simultaneous right and left ventricular pressures were analyzed,
and pressure-volume curves were constructed by using microma-
nometer tip left ventricular pressure recordings and biplane con-
trast ventriculography.10,11 In addition, coronary flow was mea-
sured by using a 0.014-inch Doppler flow wire placed in the
proximal left coronary artery before and after infusion of 18 g of
adenosine. Coronary flow reserve was calculated as the ratio of
average peak velocity during maximum hyperemia divided by
baseline average peak velocity.12,13
Results
Patients implanted with the CSD in the nonrandomized
studies were primarily male (88%), with an age at the time
of operation of 59.3  10.1 years (range, 34-87 years).
Idiopathic dilated cardiomyopathy predominated (n  35
[73%]), and the remainder of the patients had an ischemic
cause (n 13 [27%]). NYHA functional class at enrollment
was 2.9  0.5 (range, 2-4), although all patients had a
history of at least one episode of functional class III or IV.
A significant degree of cardiac remodeling and loss of
cardiac function was apparent in these patients at baseline,
with an LVEDD of 71.3  7.3 mm (range, 59-86 mm) and
an LVEF of 22.3% 8.9% (range, 10%-41%). Patients had
experienced an average of 2.0 1.8 cardiac hospitalizations
during the year preceding the operation and were receiving
a stable course of medication for at least a month before
CSD implantation.
The complete surgical procedure required an average of
2.3  0.6 hours (range, 1.6-3.7 hours) for CSD-only oper-
ations compared with 3.5 1.2 hours (range, 2.0-6.7 hours)
for procedures involving concomitant cardiac operations.
The average implantation time was 23.1  6.1 minutes
(range, 15-40 minutes) for patients receiving only the CSD,
whereas implantation time in conjunction with concomitant
cardiac procedures was slightly greater (29  11 minutes
[range, 14-67 minutes]). Crossclamp time was not required
for CSD-only implantation, and 49.7  30.3 minutes
(range, 21-125 minutes) of crossclamp time was used in
conjunction with concomitant procedures. Total cardiopul-
monary bypass time was 24.7  9 minutes (range, 20-32
minutes) for CSD-only procedures and 94.8  36 minutes
(range, 55-188 minutes) for concomitant procedures. Mean
intraoperative LVEDD reduction was 3.2 mm (4.6%). There
were no device-related intraoperative complications in this
study.
There were 8 deaths attributed to operative mortality
(Table 3), having taken place during the first 30 days after
the operation or during the initial hospitalization. This in-
cluded 1 (7%) of 15 patients in the CSD-only group and 7
(21%) of 33 patients in the concomitant surgery group.
There were 9 late deaths in total, including several not
related to heart failure (cancer in 2 patients and suboptimal
anticoagulant level in a patient with a prosthetic mechanical
heart valve). Other late deaths were attributed to pneumo-
nia, ventricular arrhythmia, progressive recurrent mitral re-
gurgitation, and cerebral hemorrhage. The 2 remaining
long-term deaths were considered cardiac failure, with 1
occurring approximately 1 month after weaning from a left
ventricular assist device. Of the 17 total deaths in the series,
5 (38%) occurred in patients with an ischemic cause, and 12
(34%) occurred in patients with an idiopathic cause. No
deaths or adverse events were CSD related.
Because of deaths and other factors, follow-up was not
obtainable for patients at all time points. At 12 months, 12
patients had died. In addition, one patient was terminated
from the study before 12 months’ follow-up as a conse-
quence of a stroke. Four patients missed the 12-month
examination, 4 patients were permanently lost to follow-up,
and 2 patients had not yet reached the 12-month time point.
TABLE 2. Late-stage heart failure relative risk factors
Late-stage heart failure with increased surgical risk as defined
by the presence of 4 of the following relative risk factors:
● LVEDD 80 mm
● Peak VO2 13 mL · kg
1 · min1 (cardiopulmonary exercise
test)
● Resting systolic BP 80 mm Hg (on clinical examination)
● Atrial fibrillation at time of enrollment or paced rhythm with
underlying atrial fibrillation
● Heart failure duration 8 y
● Exercise-induced increase in systolic BP 10%
(cardiopulmonary exercise test)
● 6-min walk 350 m (1148 feet)
● Previous cardiac surgery
● BUN 100 mg/dL
● Cachexia (clinical impression)
Peak VO2, Peak oxygen uptake; BP, blood pressure; BUN, blood urea
nitrogen.
TABLE 3. Operative mortality and late deaths
Patient group (n) Operative mortality Late deaths Total
CSD only (15) 1 4 5
Concomitant (33) 7 5 12
All patients (48) 8 9 17
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Thus, at 12 months, data were available for 25 (52%) of 48
patients.
Various factors were likely active in influencing patient
outcome. Among these were patient selection criteria. In
light of the operative mortality experienced in this series,
alterations were made in selection criteria (see late-stage
heart failure criteria) to screen out patients at unacceptably
high surgical risk. With the revised selection criteria, pa-
tients representing 7 of the 8 early deaths and 1 of the 9 late
deaths would have been screened out of the study. Kaplan-
Meier survival curves in Figure 3 demonstrate that analysis,
in which the lower curve represents all 48 patients, and the
upper curve excludes deaths of patients who would have
been screened out by the revised selection criteria. In addi-
tion, implantation techniques were refined, including fitting
the device with no greater than a 10% reduction in LVEDD.
The modified criteria are also the basis for enrollment of
patients in randomized trials currently underway with this
device.
At this time, average implantation duration is nearly 24
months for patients in the study, with a mean follow-up of
20 months for all nonrandomized patients and a minimum
follow-up of 10 months on current survivors. Follow-up
evaluations on these nonrandomized patients up to 24
months are encouraging and demonstrate that the CSD
effectively limits progressive cardiac dilation and decreased
cardiac function. Average heart size was shown to decrease
by statistically significant amounts at 12 months’ follow-up,
whereas average LVEF increased (Tables 4 and 5). 14 Func-
tional status and quality-of-life assessments, including
NYHA functional class, the Minnesota Living with Heart
Failure Questionnaire, and the Uniscale, all point toward
improvement in quality of life for these patients. Notably,
the decreases in heart size and improvements in ejection
fraction appear to be maintained at 18 to 24 months after the
operation (Figure 4). Encouraging results were seen for the
overall patient cohort, as well as for the subgroup of patients
who received only the CSD (Table 5).
Follow-up results obtained from the safety study patients
in Melbourne with ischemic heart disease and requiring
coronary artery bypass surgery are consistent with the re-
sults obtained for patients receiving the CSD in a stand-
alone procedure and those patients who required concomi-
tant mitral valve repair or replacement. In these ischemic
patients, the CSD prevented cardiac dilation and was well
tolerated.15,16 All coronary artery bypass grafts were patent
at follow-up, and cardiac symptoms were reduced in all
patients. No device-related adverse events have occurred in
this group of patients.
A subset of study patients underwent hemodynamic and
pressure-volume loop analyses at 3, 6, and 12 months’
follow-up. Values obtained for the differences in ventricular
end-diastolic pressure, right atrial mean pressure, and right
ventricular pressure ratio revealed no indication of cardiac
Figure 3. Kaplan-Meier survival curves for all patients in the
series (n  48) and a subgroup (n  40) in which patients at high
surgical risk are screened out according to revised selection
criteria.
TABLE 4. All patients at 12 mo follow-up
Before
implantation 12 mo
LVEDD, mm (n  25)* 72.8 7.1 64.1 10.6†
LVESD, mm (n  23)* 62.8 8.1 54.7 12.0†
LVEF, % (n  23)* 23.6 8.0 29.9 12.2†
MR, 0–4 (n  22)‡ 1.6 1.0 0.5 0.7†
NYHA (n  26)‡ 2.7 0.5 1.7 0.7†
MN Living with HF (n  20)‡ 30.9 19.6 25.0 21.1
Uniscale (n  18)‡ 4.6 2.3 6.3 2.2†
Mean  SD. LVESD, Left ventricular end-systolic dimension; MR, mitral
regurgitation; MN Living with HF, Minnesota Living with Heart Failure
Questionnaire; Uniscale, Quality of Life Questionnaire.
*Paired t test.
†P  .05.
‡Wilcoxon signed-rank test.
TABLE 5. CSD-only patients at 12 mo follow-up
Before
implantation 12 mo
LVEDD, mm, (n  12)* 72.7 5.5 64.4 5.4†
LVESD, mm (n  12)* 64.4 5.4 56.9 5.7†
LVEF, % (n  12)* 22.7 5.7 28.6 8.2†
MR, 0–4 (n  12)* 1.1 0.5 0.5 0.8
NYHA (n  12)‡ 2.5 0.5 1.8 0.7†
MN Living with HF (n  10)‡ 34.3 21.6 28.3 18.6
Uniscale (n  10)‡ 4.5 2.2 6.1 2.2†
Mean  SD. LVESD, Left ventricular end-systolic dimension; MR, mitral
regurgitation; MN Living with HF, Minnesota Living with Heart Failure
Questionnaire; Uniscale, quality-of-life questionnaire.
*Paired t test.
†P  .05.
‡Wilcoxon signed-rank test.
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constriction or diastolic dysfunction (Table 6). Left ventric-
ular pressure-volume analysis supported these findings. Fig-
ure 5 depicts pressure-volume loop data for a patient im-
planted with the device only, with no other concomitant
cardiac procedures. These results are representative of the
series as a whole17 and illustrate a lack of diastolic impair-
ment or development of constrictive physiology.
Coronary flow capacity was evaluated by using intra-
coronary adenosine administration. All patients studied
demonstrated a normal coronary flow reserve with no flow
impairment (Table 7). Most patients were receiving an
extensive list of cardiac medications, including angiotensin-
converting enzyme inhibitor/angiotensin receptor blocker
and -blockers (Table 8). During follow-up, these medica-
tions were generally maintained.
Discussion
Progressive heart failure is characterized by loss of cardiac
function associated with maladaptive changes in myocardial
gene expression and neuroendocrine activity, leading to
progressive increases in heart size. Increased ventricular
wall stress and myocardial stretching resulting from this
increase in chamber size are thought to play a role in
furthering development toward end-stage disease. Reduc-
tion of wall stress and myocardial stretching might be
important means for mitigating heart failure progression.
One possible approach to accomplish this goal is through
passive containment of the heart with the CSD. Results from
preclinical and clinical evaluation support this premise.
Chaudhry and colleagues18 have reported reduced left
ventricular volumes and improved cardiac function param-
TABLE 6. Hemodynamic assessment of constriction; 3-, 6-,
and 12-month follow-up
Follow-up
3 mo
(n  15)
6 mo
(n  11)
12 mo
(n  6)
LVEDP-RVEDP (mm Hg) 5.9 5.3 5.3 4.5 7.6 7.1
RV ESEDP ratio 0.28 0.11 0.38 0.08 0.32 0.21
RAMP (mm Hg) 8.7 5.6 11.0 4.6 10.2 6.9
Mean  SD. LVEDP, Left ventricular end-diastolic pressure; RVEDP, right
ventricular end-diastolic pressure; RV ESEDP, ratio of right ventricular
end-systolic pressure/right ventricular end-diastolic pressure; RAMP, right
atrial mean pressure.
Figure 5. Pressure-volume loop analysis. Cardiac catheterization
and biplane contrast ventriculography were used to capture
simultaneous pressure-volume data at baseline and follow-up
through 12 months. Representative results for a device-only pa-
tient are plotted as pressure-volume loops, demonstrating de-
creases in end-systolic and end-diastolic volumes and a trend
toward lower end-diastolic pressure at follow-up.
Figure 4. Changes in LVEDD and LVEF at follow-up. The mean 
SEM changes in LVEDD (in millimeters) and LVEF (percentage)
during follow-up are shown, along with the numbers of patients
at each time point for whom baseline and follow-up values were
available. The final follow-up (18-24 months) represents com-
bined data for patients with latest follow-up at 18 months (n  4)
or 2 years (n  9).
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eters in CSD-treated animals by using a microembolic ca-
nine heart failure model. At 3 months’ follow-up, left ven-
tricular end-diastolic volume (LVEDV) was reduced (68 
4 mL at baseline vs 61 4 mL at 3 months [mean SEM],
P  .005) but increased in the untreated control group (67
 5 mL at baseline vs 83  8 mL at 3 months). LVEF was
increased (34%  1% at baseline vs 41%  1% at 3
months, P  .005) in animals with heart failure treated with
the CSD but decreased in the control group (36%  1% at
baseline vs 28%  2% at 3 months). Similar results have
been demonstrated at 6 months’ follow-up.
LVEDV and LVEF at follow-up were statistically dif-
ferent between the control and CSD treatment groups. Also,
at 3 months’ follow-up, regional wall motion was greater in
the CSD-treated group compared with that in the control
heart failure group, whereas mitral valve regurgitation was
eliminated in the treatment group. A trend toward increased
left ventricular end-diastolic pressure in the control group
and a decrease in the treatment group at follow-up was also
noted.
Power and associates19 used a high-rate pacing ovine
model of heart failure and reported similar findings. Heart
size (left ventricular diastolic area) was maintained or re-
duced with CSD treatment in moderate and more advanced
heart failure, despite continued high-rate pacing. Cardiac
function also improved with CSD treatment, as reflected by
improved LVEF, fractional shortening, positive dP/dt, and
negative dP/dt. Functional improvement was noted irrespec-
tive of whether the CSD was implanted in patients with
moderate or more advanced heart failure.
Histomorphologic analysis was performed on cardiac
tissue samples from dogs with microemboli-induced heart
failure at 3 months’ follow-up. Compared with the control
group, the tissue from the CSD-treated study group showed
less myocyte hypertrophy, less interstitial fibrosis, and
greater capillary density.20 Further testing in this animal
model demonstrated enhanced myocyte function (percent-
age of shortening and peak derivative of shortening and
relaxation) in the CSD-treated group compared with that in
the control group.20
Biochemical factors implicated in possible mechanisms
of actions for CSD therapy have been examined. Sabbah
and coworkers21 reported that stretch protein levels (p21ras,
c-fos, and p38/MAP kinase) were at lower levels in the
CSD-treated group, and Ca2 cycling was improved (on the
basis of an increase in the ratio of Ca2 ATPase/phospho-
lamban and a downregulation of protein phosphatase activ-
ity) in the CSD-treated group.22 In addition, the expression
ratio of Bcl-2/Bax was altered after CSD implantation,
suggesting an attenuation in proapoptotic signaling in car-
diomyocytes.23 These findings suggest that the CSD can
prevent or minimize maladaptive gene expression and phe-
notypic transformation. In summary, these studies indicate
that the CSD, by supporting the ventricle and reducing
stress-mediated myocardial stretching, can halt progressive
remodeling and perhaps allow for reverse remodeling.
Preclinical studies indicate no signs of a constrictive
pattern on the basis of analysis of filling pressures and
pressure-volume loops.24 In addition, animals with heart
failure evaluated at 3 months after CSD implantation dem-
onstrated a normal response to severe volume load by
increasing LVEDV, LVEF, and left ventricular stroke vol-
ume.25
Clinical study results also indicate that patients receiving
the CSD do not exhibit a constrictive physiology. As part of
the safety study, 15 patients were entered into a substudy
designed to address this question.26 Patients underwent
pressure-volume loop analysis and detailed hemodynamic
monitoring, including assessment of left and right ventric-
ular end-diastolic pressures, right atrial pressures, right ven-
tricular pressure ratios, and right ventricular indices. Pa-
TABLE 8. Cardiac medications at baseline and 12 months
Cardiac medications
Baseline
(% of patients)
12 mo
(% of patients)
ACEI/ARB 90/8 82/14
Diuretic 98 95
Digoxin 72 73
-Blocker 68 82
Amiodarone 19 9
Other 72 59
ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker.
TABLE 7. Coronary flow reserve
Follow-up (mo)
3 (n  11) 6 (n  7) 12 (n  4)
Baseline APV (cm/s) 25.0 8.0 24.0 12.0 28.0 8.0
APV after adenosine (cm/s) 71.0 19.0 64.0 18.0 88.0 18.0
Coronary flow reserve* 2.9 0.6
(range, 2.1–3.7)
3.1 0.9
(range, 2.2–4.4)
3.2 0.4
(range, 2.8–3.7)
Mean  SD.
APV, Average peak velocity.
*Normal values are greater than 2.0.
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tients were followed up to 12 months after CSD
implantation. On the basis of these analyses, there was no
evidence of constriction. In addition, coronary flow reserve
measurements conducted in these patients showed normal
coronary flow without signs of coronary impairment.
Tissue reaction between the CSD and the heart does not
appear to contribute to a constrictive physiology and should
not interfere with most future cardiac surgeries. Neverthe-
less, surface fibrosis associated with the CSD might com-
plicate future cardiac surgeries and might interfere with
visualization of the cardiac architecture, including epicar-
dial coronary arteries should a redo operation, such as
coronary artery bypass, be required. Experience in animal
models suggests that the normal fibrotic response to the
CSD is self-limiting and thin in cross-section, and limited
clinical experience suggests a similar response in human
subjects. However, adequate clinical data are not yet avail-
able to determine the ease of access to coronary arteries or
other cardiac structures if a future redo operation is re-
quired.
Coronary artery bypass graft surgery can be safely per-
formed in conjunction with CSD implantation. After posi-
tioning the CSD, small openings are created in the device
fabric to access anastomotic sites on epicardial coronary
arteries. In a limited series of patients undergoing coronary
artery bypass grafting, graft patency was evaluated by
means of coronary angiography 6 months after the opera-
tion, at which time all grafts remained patent.8
Patients with end-stage cardiomyopathy frequently expe-
rience severe mitral regurgitation, which contributes to
heart failure progression and is predictive of poor out-
come.27 Mitral regurgitation in the context of cardiomyop-
athy is believed to result from dilation of the mitral annular-
ventricular apparatus with altered ventricular geometry or
from ischemic papillary muscle dysfunction.28-30 In patients
with significant mitral valve regurgitation, mitral valve re-
pair or replacement might be performed in conjunction with
the CSD implantation. These concomitant procedures have
been successfully performed in more than 65 patients to
date, with slight modifications to the CSD implantation
procedure.
Several limitations are inherent in this study, which
represented the initial clinical experience for use of the
Acorn CorCap CSD in patients with idiopathic or ischemic
dilated cardiomyopathy. As such, patients were not random-
ized, control patients were not enrolled, and blinding was
not used. In addition, a complete record of follow-up was
not obtainable for some of the patients. Nevertheless, im-
provements seen in terms of cardiac structure and function
were similar to those observed in several animal models of
heart failure.
In conclusion, the CSD provides a promising surgical
therapy for dilated cardiomyopathy. On the basis of exten-
sive preclinical studies, the CSD not only halts ventricular
dilation but also appears to promote ventricular reverse
remodeling without any safety issues. Similar results are
reflected in the initial clinical experience, with up to 2 years
of patient follow-up. The CSD appears to be a safe product
and might improve cardiac function. On the basis of these
studies, randomized clinical trials are currently underway in
Europe and North America. This surgical approach provides
additional evidence supporting aggressive management of
ventricular remodeling in the treatment of heart failure.
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